Used in pharmaceutical research as a targeted protein degrader, specifically functioning as a heterobifunctional PROTAC (proteolysis-targeting chimera). It is designed to selectively recruit specific disease-related proteins to an E3 ubiquitin ligase, inducing ubiquitination and subsequent degradation by the cell's proteasome system. This compound shows potential in oncology research due to its ability to modulate hard-to-target proteins involved in cancer progression. Its structure enables enhanced cell permeability and target specificity, making it valuable in developing therapies for resistant or undruggable targets.